Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
This market may increase by 16x from today's size to reach $100 billion by the end of the decade, according to Goldman Sachs Research. And right now, Lilly's two drugs prescribed for weight loss patients -- Mounjaro and Zepbound -- are bringing in billions of dollars in revenue But Lilly isn't alone in the market, and in the coming years, this space could become more crowded. Today, Lilly competes with Novo Nordisk , and in the future, companies like biotech giant Amgen and smaller biotech Viking Therapeutics to big pharma company Pfizer could enter the market with rival products. These players, as well as many others, are studying candidates in clinical trials right now. But my prediction is that even when stronger competition is present, Lilly will continue to dominate this billion-dollar market -- and for one key reason. Mounjaro and Zepbound First, let's take a quick look at why Lilly's drugs and others of the same class are so popular. Mounjaro and Zepbound are the same d
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- WeightWatchers CEO Sima Sistani is leaving the company [Yahoo! Finance]Yahoo! Finance
- PFE vs. NVO: Which Stock Is the Better Value Option? [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk's Wegovy-Fueled Gains Fading as Analyst Doubts Grow [Yahoo! Finance]Yahoo! Finance
- She took Ozempic, now she can't eat without vomiting. Lawsuit claims the drug made her ill [USA TODAY]USA TODAY
- Compounding pharmacies caught in counterfeit controversy [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 8/8/24 - Beat
NVO
Sec Filings
- 9/24/24 - Form 6-K
- 9/20/24 - Form 6-K
- 9/16/24 - Form 6-K
- NVO's page on the SEC website